Patient Demographics and HER2 Expression Results
| Patient no. | Age (y) | Metastatic sites at enrollment | Confirmatory HER2 IHC of primary breast cancer | Suggestive foci on 89Zr-trastuzumab PET/CT? | Image-guided biopsy results |
| 1 | 46 | Bone, liver | 0 | None | |
| 2 | 41 | Nodes | 1+ | Nodes (SUVmax, 4.6) | IHC, 3+ |
| 3 | 58 | Bone, liver, nodes | 0 | Bone (SUVmax,7.1) | IHC, 1+ |
| 4 | 69 | Bone, liver, nodes | 0 | None | |
| 5 | 38 | Bone, liver, nodes | 1+ | Bone (SUVmax, 5.9) | IHC, 2+; FISH, failure; MSK-IMPACT, amplified |
| 6 | 42 | Nodes, adrenal | 1+ | Adrenal (SUVmax, 9.2) | IHC, 2+; FISH, 1.4 |
| 7 | 83 | Bone, liver, nodes, lung | 1+ | Bone (SUVmax, 9.7) | IHC, 1+ |
| 8 | 54 | Bone, liver, nodes, lung | 0 | None | |
| 9 | 48 | Bone, liver, nodes, pleura | 1+ | None |
IHC = immunohistochemistry score.
All 9 women had primary invasive ductal breast cancer.